

February 23, 2023

Dear Shareholder,

Please find enclosed an invitation to attend Genmab A/S' 2023 Annual General Meeting to be held on

Wednesday, March 29, 2023 at 14:00 PM CEST at
Copenhagen Marriott Hotel
Kalvebod Brygge 5
1560 Copenhagen V
Denmark

As a co-founder of Genmab, I am extremely motivated by the progress we have made, both since I became CEO and over the past year.

In 2010, when I became CEO of Genmab, there was an imperative to outline a new strategy – one that would reposition the company to become financially sustainable and allow us to invest in our world-class antibody products and technologies. Soon after we launched our successful strategy, we articulated an ambitious vision for the company – that by 2025, our own product has transformed cancer treatment, and we have a pipeline of KYSO antibodies. To support this vision, we outlined how we would build our capabilities and teams, and we aligned on a series of goals and milestones that we committed to reaching by 2025.

I am proud that we have met most of those goals and many more are within reach, giving us an extremely solid foundation on which to continue to build Genmab. Together with Genmab's leadership team we have captured our aspirations for the future with a new vision, that by 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.

While we will continue to create and develop new treatment concepts in oncology, we will apply a rigorous approach in identifying areas outside of oncology where our science and expertise may potentially make the biggest difference for patients, with the ultimate goal of improving the lives of as many people as possible. As a scientist and immunologist, I am truly excited by the potential of our antibodies and by the possibilities for Genmab in 2023, 2030 and beyond.

I can say with confidence that this is not my story alone or the story of our global leadership team – it is the story of our talented and unstoppable Genmab team, of our collaboration partners who believe in the power of antibody therapies, of our supportive Board of Directors, the patients who participate in our clinical trials and their families, the investigators who help us trailblaze innovations, and our shareholders who believe in our vision.

I look forward to further describing our progress at the Annual General Meeting. If you are unable to participate, I encourage you to return the enclosed proxy, or to vote by post. We are at the beginning of a fantastic KYSO future that we are creating together, and I thank you for your continued support.

Sincerely yours,



Jan van de Winkel, Ph.D.
President & Chief Executive Officer